Right. That is not a problem.
I want to go back to Mr. Keon and Mr. Gray now.
As we know, there are many differences between public policies that would like to see pharmaceutical research companies and brand-name manufacturers on the one hand, and those that would like to see companies that develop generic drugs, on the other.
Is common ground or a consensus with regard to intellectual property between the two providers of pharmaceutical products possible?